Elliptic Laboratories ASA

As of June 30, 2026, Elliptic Laboratories ASA carries a market capitalization of 366.38M, placing it among publicly traded companies globally. Its enterprise value stands at 323.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Elliptic Laboratories ASA's next confirmed earnings release is scheduled for November 19, 2026.

As of June 30, 2026, Elliptic Laboratories ASA has 126.34M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.75, and the price-to-book ratio stands at 1.74.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 323.27M versus a market cap of 366.38M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Elliptic Laboratories ASA maintains a current ratio of 8.77, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.18, indicating elevated leverage, while an interest coverage ratio of -0.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Elliptic Laboratories ASA posted a negative return on equity (ROE) of -48.32, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -43.71, reflecting losses generated across the asset base. The company generates approximately 1.31M in revenue per employee across its workforce of 87.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Elliptic Laboratories ASA recorded 91.80M in income tax expense. The company reported a pretax loss of -33.13M and -124.92M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Elliptic Laboratories ASA's stock has declined approximately 71.72% over the past 52 weeks. The 50-day moving average sits at 3.18, while the 200-day moving average is 3.37.

Over the twelve months ended June 30, 2026, Elliptic Laboratories ASA generated 114.05M in revenue and converted that into -124.92M in net income, yielding earnings per share of -1.08. EBITDA reached -1.52M, while operating income came in at -30.05M.

As of June 30, 2026, Elliptic Laboratories ASA holds 56.16M in cash and equivalents against 13.05M in total debt, resulting in a net debt position of -56.16M. Total book value stands at 211.13M, with working capital of 132.39M providing operational flexibility.

Elliptic Laboratories ASA produced -22.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -17.92M in capital expenditures, free cash flow totaled -40.82M - equivalent to -0.38 per share.

Over the twelve months ended June 30, 2026, Elliptic Laboratories ASA posted a gross margin of 27.19, reflecting its pricing power and cost economics. The operating margin of -26.35 and net profit margin of -109.53 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.10, meaning Elliptic Laboratories ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Elliptic Laboratories ASA's most recent stock split took place on September 30, 2021 with a 1:10 split ratio.